Edwin Jacobs, MD
Hematology & Oncology · Burbank, CANPI 1366462939
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 9.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,979 and has fallen 98.8% since, to $35 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 191 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$357
- Amgen$314
- Novartis$304
- Genentech USA, Inc.$238
- Seagen Inc.$235
- Takeda Pharmaceuticals U.S.A., Inc.$219
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,76798%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $357 |
| Amgen | 13 | $314 |
| Novartis | 16 | $304 |
| Genentech USA, Inc. | 11 | $238 |
| Seagen Inc. | 12 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $219 |
| Eisai Inc. | 9 | $197 |
| Johnson & Johnson(2 entities) | 11 | $160 |
| Bristol Myers Squibb | 6 | $157 |
| Sanofi | 9 | $147 |
| Merck | 8 | $147 |
| AstraZeneca(2 entities) | 8 | $131 |
| E.r. Squibb & Sons, L.L.C. | 7 | $125 |
| Incyte Corporation | 6 | $122 |
| Regeneron Healthcare Solutions, Inc. | 4 | $115 |
| Boehringer Ingelheim | 6 | $100 |
| Puma Biotechnology, Inc. | 5 | $92 |
| Gilead | 3 | $86 |
| Bayer | 5 | $86 |
| Lilly USA, LLC | 3 | $68 |
| Clovis Oncology, Inc. | 3 | $61 |
| GSK | 2 | $57 |
| Astellas Pharma US Inc | 3 | $56 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| AbbVie | 2 | $41 |
| ADC Therapeutics America, Inc. | 1 | $36 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| EUSA Pharma (US) LLC | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Shionogi Inc | 1 | $13 |
How this compares
$3,824 in reported general payments places this provider in the 50th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 29 | $392,940 |
| CalquenceAcalabrutinib Maleate | 24 | $358,094 |
| XtandiEnzalutamide | 26 | $353,150 |
| Lenalidomide | 28 | $298,411 |
| TasignaNilotinib Hcl | 16 | $255,130 |
| RevlimidLenalidomide | 17 | $217,604 |
| ImbruvicaIbrutinib | 11 | $125,504 |
| EliquisApixaban | 60 | $56,097 |
| XareltoRivaroxaban | 67 | $55,194 |
| Abiraterone Acetate | 12 | $19,557 |
| Anastrozole | 124 | $2,484 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $2,222 |
| Butalbital-Aspirin-CaffeineButalbital/Aspirin/Caffeine | 11 | $1,832 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 76 | $1,109 |
| Alprazolam | 84 | $711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $122 | $392,94029 claims |
| AstraZenecaCalquence | $131 | $358,09424 claims |
| Astellas Pharma US IncXtandi | $56 | $353,15026 claims |
| NovartisTasigna | $304 | $255,13016 claims |
| Bristol Myers SquibbRevlimid | $157 | $217,60417 claims |
| PfizerEliquis | $357 | $56,09760 claims |
| Johnson & JohnsonXarelto | $160 | $55,19467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Burbank
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.